Dogwood Therapeutics, Inc. (DWTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.69 (-1.74%), Market cap $0.06B, 52-week low–high $1.34 ~ $7.91.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat
Financial statements, price targets, institutional (13F) holdings and related news for Dogwood Therapeutics, Inc. are updated in real time on BlackAll Trade.
Dogwood Therapeutics, Inc. trades at $1.69 (-1.74%). Real-time quotes and charts are available on BlackAll Trade.
Dogwood Therapeutics, Inc. has a market cap of about $0.06B.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a